Syros Pharmaceuticals, Inc.
General ticker "SYRS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.0M (TTM average)
Syros Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -15.2%.
Estimated limits based on current volatility of 0.5%: low 0.00$, high 0.00$
Factors to consider:
- Total employees count: 68 (-42.4%) as of 2023
- Top business risk factors: Operational and conduct risks, Labor/talent shortage/retention, Geopolitical risks, Economic downturns and volatility, Cybersecurity threats
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.72$, 8.54$]
- 2024-12-30 to 2025-12-30 estimated range: [1.72$, 5.69$]
Financial Metrics affecting the SYRS estimates:
- Negative: with PPE of -1.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -60.63 <= 0.33
- Positive: Investing cash flow per share per price, % of 20.64 > -0.66
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 2.83 <= 3.41
- Negative: Shareholder equity ratio, % of 9.91 <= 18.93
- Negative: negative Net income
Short-term SYRS quotes
Long-term SYRS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $23.49MM | $14.88MM | $9.94MM |
| Operating Expenses | $122.91MM | $150.75MM | $138.92MM |
| Operating Income | $-99.42MM | $-135.87MM | $-128.99MM |
| Non-Operating Income | $12.86MM | $41.22MM | $-35.59MM |
| Interest Expense | $3.91MM | $4.13MM | $5.13MM |
| R&D Expense | $99.87MM | $111.94MM | $108.15MM |
| Income(Loss) | $-86.56MM | $-94.65MM | $-164.57MM |
| Profit(Loss)* | $-86.56MM | $-94.65MM | $-164.57MM |
| Stockholders Equity | $85.22MM | $127.74MM | $16.66MM |
| Assets | $182.94MM | $244.49MM | $168.17MM |
| Operating Cash Flow | $-99.54MM | $-123.06MM | $-109.71MM |
| Capital expenditure | $1.25MM | $1.24MM | $0.27MM |
| Investing Cash Flow | $-52.65MM | $67.19MM | $37.34MM |
| Financing Cash Flow | $70.51MM | $131.04MM | $43.46MM |
| Earnings Per Share** | $-13.84 | $-7.49 | $-5.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.